# Healthpeak Properties Inc. (PEAK) — Investment Thesis

**Exchange:** NYSE  
**Coverage as of:** 2026-Q2  
**Updated:** 2026-05-13  
**Tier:** Free primer (steps 1 & 3 of 19)  
**Sibling pages:** /stocks/PEAK/financials · /stocks/PEAK/memo

> This page shows the free thesis context (business model + recent catalysts).
> The full investment thesis (moat analysis, DCF, scenarios, risk register) is available
> via GET /api/v1/research/PEAK/memo ($2.00, Bearer token).

## Business Model

---
ticker: PEAK
step: 01
generated: 2026-05-13
source: quick-research
note: Ticker changed from PEAK to DOC (NYSE:DOC) effective March 4, 2024, following merger with Physicians Realty Trust
---

### Healthpeak Properties, Inc. (PEAK/DOC) — Business Overview

#### Business Description
Healthpeak Properties (NYSE: DOC, formerly PEAK) is a leading healthcare REIT and one of the largest in the United States, focused on life science and outpatient medical real estate. Following the March 2024 all-stock merger with Physicians Realty Trust, Healthpeak transformed into a pure-play healthcare real estate company with ~$20B in total assets. The combined portfolio generates net operating income from approximately 54% medical office buildings, 35% life science properties, and 11% CCRCs (Continuing Care Retirement Communities) and other assets. The merger also created $50–$70M in annual cost synergies through property management internalization and G&A consolidation.

#### Revenue Model
Revenue is generated from lease income on healthcare real estate under long-term leases. Medical office buildings (MOBs) use modified gross or triple-net structures with 5.8% average cash re-leasing spreads on renewals — a strong indicator of pricing power. Life science properties lease to biotech, pharmaceutical, and genomic research companies under long-term leases. The company is also the external manager of Janus Living, Inc. (a senior housing spinoff IPO), retaining 81.6% ownership and earning management fees.

#### Products & Services
- **Medical Office Buildings (54% of NOI):** Outpatient facilities, physician office buildings, ambulatory surgery centers — leased to health systems (Kaiser, HCA, Tenet), physician groups, and academic medical centers
- **Life Science (35% of NOI):** Laboratory and R&D facilities in Boston, San Francisco, San Diego — leased to biotech (Pfizer, Eli Lilly, BioNTech, AstraZeneca), genomics, and med-tech companies
- **CCRCs/Other (11%):** Senior living communities; Janus Living Inc. IPO platform (34 communities, 10,422 units) — Healthpeak retains 81.6% post-IPO
- **Development Pipeline:** $500M in 2025 investments at 8%+ weighted average yields

#### Customer Base & Go-to-Market
Medical office tenants are typically hospital systems, academic medical centers, and physician groups with long operational histories and strong credit profiles. Life science tenants range from investment-grade pharma majors to venture-backed biotech companies — the latter creating credit risk during downturns in biotech funding. No single tenant exceeds ~5% of NOI.

#### Competitive Position
Healthpeak competes with Ventas (VTR), Welltower (WELL), and Alexandria Real Estate Equities (ARE) in healthcare REIT. Post-merger scale (10M+ square feet of MOBs renewed; ~35M+ SF total portfolio) creates operating leverage advantages in property management. The medical office segment benefits from an aging U.S. population and the shift of care from inpatient (hospitals) to outpatient settings — a secular trend accelerating healthcare real estate demand.

#### Key Facts
- Founded: 1985 (as Health Care Properties of America)
- Headquarters: Denver, CO
- Employees: ~700
- Exchange: NYSE (DOC, formerly PEAK until March 2024)
- Sector / Industry: Real Estate / Healthcare REITs
- Market Cap: ~$12B

## Recent Catalysts

---
ticker: PEAK
step: 12
generated: 2026-05-13
source: quick-research
note: Now trades as NYSE:DOC following March 2024 Physicians Realty Trust merger
---

### Healthpeak Properties, Inc. (PEAK/DOC) — Investment Catalysts & Risks

#### Bull Case Drivers

1. **Physicians Realty Merger Creates Scale + $70M Synergy Run Rate** — The March 2024 merger with Physicians Realty Trust was transformative: it nearly doubled Healthpeak's medical office portfolio, generated $50M+ in synergies in year one (exceeding guidance midpoint), and positioned the combined company as one of the largest outpatient medical real estate platforms in the U.S. With 10M+ square feet of MOB renewals posting 5.8% average cash re-leasing spreads, the medical office segment is demonstrating genuine pricing power driven by the secular shift of care to outpatient settings and an aging U.S. population. The full $70M synergy run rate, combined with $500M in new development at 8%+ yields, creates a multi-year AFFO growth engine that doesn't depend on life science recovery.

2. **Janus Living IPO Unlocks Hidden Value in Senior Housing** — Healthpeak's plan to IPO Janus Living, Inc. — a 34-community, 10,422-unit senior housing platform — is a significant value unlock. Healthpeak retains 81.6% post-IPO, with that stake valued at approximately $5.7B. Janus reported 35% revenue growth and 42% adjusted EBITDA growth in Q1 2026, demonstrating the strength of senior housing fundamentals as the COVID-impacted operating environment normalizes. Management expects the Janus transaction to be earnings-neutral in 2026 and $0.04/share accretive once proceeds are redeployed into debt paydown or investments. At current DOC/PEAK stock prices (~$16), the Janus stake alone represents significant embedded value relative to Healthpeak's ~$12B market cap.

3. **Life Science Inflection Point Building — 2027 Recovery Thesis** — While near-term life science occupancy (~77.7%) is below historical norms, management sees early signs of an inflection: Q1 2026 FFO beat estimates by $0.02, full-year guidance was raised, and lab re-leasing activity is progressing despite 30%+ vacancy in Boston and Bay Area. Life science real estate tends to recover 12–18 months after biotech funding rebounds — and 2024–2025 saw significant AI-driven drug discovery investment (Moderna, Pfizer, BioNTech) that is beginning to translate into new lab space demand. As Healthpeak's $1B portfolio rebalancing (asset sales, recapitalizations) deleverages the balance sheet, the company is positioned for a material re-rating if life science occupancy improves toward 85%+ in 2027.

#### Bear Case Risks

1. **Life Science Vacancy Crisis — 30%+ Vacancy in Core Markets** — Boston and San Francisco/Bay Area life science markets have vacancy rates exceeding 30% — the worst since the 2008 financial crisis — driven by oversupply from aggressive 2020–2022 lab development combined with a significant contraction in biotech venture funding. Jefferies downgraded Healthpeak specifically on lab market concerns, noting trailing biotech VC funding was down 10% YoY. Healthpeak faces ~400,000 SF of life science expirations in 2026, and re-leasing at current market rents represents negative mark-to-market spreads. Until lab vacancy clears (which could take 18–36 months), this segment will drag overall AFFO growth and investor sentiment.

2. **$650M Debt Maturity + Rising Interest Costs** — $650M in senior notes mature in June 2026, requiring refinancing at materially higher rates than the original coupon — adding ~$20M in annual interest expense. At 7.5x Net Debt/EBITDA with modest AFFO growth, the refinancing pressure reduces financial flexibility. G&A costs are running ~$5M higher than prior guidance. The combination of higher debt costs, elevated G&A, and life science headwinds creates a tighter-than-expected path to meaningful AFFO/share growth in 2026 — Evercore ISI downgraded the stock from Outperform to In-Line citing valuation vs. this constrained near-term growth profile.

3. **Biotech Tenant Credit Risk During Funding Drought** — Healthpeak's life science tenants include both investment-grade pharma (highly stable) and venture-backed biotech companies (highly variable credit quality). During periods of reduced VC funding and IPO market closures for biotech, smaller tenant defaults or early lease terminations can spike vacancy unexpectedly. The 2022–2023 biotech funding drought already contributed to current vacancy levels; any renewal of macro risk-off sentiment that reduces biotech IPO/M&A activity could extend the lab vacancy period and force additional concessions (free rent, TI allowances) that compress cash re-leasing spreads below the 3.5% quarterly level already trending lower.

#### Upcoming Events
- **Q2 2026 Earnings (July 2026)**: Update on life science leasing activity and occupancy trajectory; Janus Living IPO timeline
- **$650M Debt Refinancing (June 2026)**: New coupon rate and structure will quantify the interest expense headwind for the remainder of 2026
- **Janus Living IPO**: Timing and pricing will establish a market value for Healthpeak's 81.6% stake — potential major catalyst for DOC/PEAK stock re-rating
- **Life Science Occupancy Recovery**: Quarterly leasing activity and commencement data are the primary leading indicators

#### Analyst Sentiment
Mixed, trending cautious: Evercore ISI downgraded from Outperform to In-Line (May 2026) citing valuation. Jefferies downgraded on lab market concerns. Despite downgrades, mean analyst price target is ~$19.47 (vs. current ~$16.29 — implying 19.5% upside). The Janus Living IPO and life science recovery are the two catalysts needed to re-engage analyst upgrades. At ~9x FFO as Adjusted and ~7.4% dividend yield, valuation screens inexpensive; the risk is that AFFO growth remains constrained by life science headwinds through 2026–2027.

#### Research Date
Generated: 2026-05-13

## Full Investment Thesis (Premium)

The full research tier adds these thesis-critical dimensions:

- Moat Analysis — durable competitive advantages, switching costs, network effects
- Investment Thesis — variant perception, what has to be true, why market may be wrong
- Bull / Base / Bear Scenarios — probability weights, catalysts, price targets
- Risk Register — macro, competitive, execution, regulatory risks with materiality ratings
- Management Quality — capital allocation track record, incentive alignment
- DCF Valuation — 10-year model with sensitivity matrix

**API endpoint:** GET /api/v1/research/PEAK/memo

## Navigation

- Overview: /stocks/PEAK
- Financials: /stocks/PEAK/financials
- Thesis (this page): /stocks/PEAK/thesis
- Investment Memo: /stocks/PEAK/memo
- Coverage universe: /stocks